HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aravinda M de Silva Selected Research

Dengue (Dengue Fever)

1/2022A conserved set of mutations for stabilizing soluble envelope protein dimers from dengue and Zika viruses to advance the development of subunit vaccines.
11/2021Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins.
10/2021Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies.
6/2021Evaluation of a new point-of-care test to determine prior dengue infection for potential use in pre-vaccination screening.
1/2021Determining dengue virus serostatus by indirect IgG ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a prospective population-based study.
1/2021Performance of Dried Blood Spots Compared with Serum Samples for Measuring Dengue Seroprevalence in a Cohort of Children in Cebu, Philippines.
1/2021Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
1/2020Serologic surveillance of maternal Zika infection in a prospective cohort in Leon, Nicaragua during the peak of the Zika epidemic.
1/2020Zika virus infection enhances future risk of severe dengue disease.
1/2019Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Aravinda M de Silva Research Topics

Disease

51Infections
01/2022 - 06/2007
39Dengue (Dengue Fever)
01/2022 - 03/2010
10Severe Dengue
01/2017 - 09/2010
7COVID-19
01/2022 - 01/2020
7Zika Virus Infection
01/2020 - 01/2017
7Coinfection
05/2017 - 09/2009
4Virus Diseases (Viral Diseases)
11/2020 - 10/2014
4Yellow Fever
01/2018 - 02/2017
3Flavivirus Infections
01/2019 - 12/2005
3Lyme Disease (Disease, Lyme)
06/2007 - 02/2003
2Convalescence
01/2018 - 01/2017
1Severe Acute Respiratory Syndrome
01/2022
1Common Cold
05/2021
1Communicable Diseases (Infectious Diseases)
01/2021
1Breakthrough Infections
01/2021
1Viremia
01/2018
1Acquired Immunodeficiency Syndrome (AIDS)
01/2018
1Hepatitis B
01/2018
1Japanese Encephalitis
01/2018
1Cytokine Release Syndrome
07/2015
1Fever (Fevers)
02/2015
1Human Influenza (Influenza)
02/2014
1Shock
03/2012
1Arthritis (Polyarthritis)
06/2007
1West Nile Fever
12/2005
1Venezuelan Equine Encephalomyelitis
09/2003

Drug/Important Bio-Agent (IBA)

35AntibodiesIBA
12/2021 - 12/2005
32Neutralizing AntibodiesIBA
01/2022 - 03/2010
28VaccinesIBA
01/2022 - 02/2003
25EpitopesIBA
12/2021 - 09/2009
15Proteins (Proteins, Gene)FDA Link
01/2022 - 12/2005
12Monoclonal AntibodiesIBA
01/2019 - 03/2010
8Dengue VaccinesIBA
06/2021 - 01/2012
7AntigensIBA
01/2022 - 06/2013
6Immune Sera (Antisera)IBA
11/2021 - 01/2012
6Immunoglobulin G (IgG)IBA
06/2021 - 10/2016
4Blocking AntibodiesIBA
01/2018 - 03/2012
4CytokinesIBA
01/2018 - 03/2012
4Fc Receptors (Fc Receptor)IBA
01/2016 - 06/2011
3Subunit VaccinesIBA
01/2022 - 10/2016
3Glycoproteins (Glycoprotein)IBA
12/2021 - 01/2012
3Peptides (Polypeptides)IBA
11/2021 - 12/2017
3Attenuated VaccinesIBA
01/2018 - 01/2017
3Broadly Neutralizing AntibodiesIBA
05/2017 - 02/2015
2EnzymesIBA
11/2021 - 01/2018
2ImmunosorbentsIBA
11/2021 - 01/2018
2Membrane Proteins (Integral Membrane Proteins)IBA
11/2021 - 06/2007
2T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
01/2017 - 08/2015
2OspA proteinIBA
09/2003 - 02/2003
1B-Lymphocyte Epitopes (B-Cell Epitope)IBA
11/2021
1Immunoglobulins (Immunoglobulin)IBA
06/2021
1Viral RNAIBA
11/2020
1Virus-Like Particle VaccinesIBA
01/2018
1Pharmaceutical PreparationsIBA
01/2018
1difluprednateFDA Link
01/2018
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
10/2016
1Immunoglobulin M (IgM)IBA
10/2016
1Syk KinaseIBA
07/2015
1InflammasomesIBA
01/2015
1Viral AntigensIBA
10/2014
1Immunoglobulin Fab FragmentsIBA
10/2014

Therapy/Procedure

2Therapeutics
09/2010 - 12/2005